Insights from ESMO24 Day 3

The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at the Fira Barcelona Gran Via.

This significant event, organized by the European Society for Medical Oncology (ESMO), attracted over 30,000 participants, including healthcare professionals, researchers, patient advocates, and industry representatives from around the globe.

The congress featured nearly 300 sessions, presenting over 2,000 abstracts, with a focus on the latest advancements in cancer research and treatment. Key topics included new therapeutic combinations for various cancers, the long-term effects of immunotherapy, and innovative approaches integrating artificial intelligence into cancer care.

ESMO shared some insights from the conference on social media.

Can the promise of multi-cancer Early Detection tests become a reality?

Technical improvements are needed to overcome variable test sensitivities and high false positive rates, but recent progress is encouraging.

Immunotherapy plus neoadjuvant chemotherapy in localised muscle-invasive bladder cancer

First practice-changing results presented with immunotherapy plus neoadjuvant chemotherapy in localised muscle-invasive bladder cancer.

Addition of durvalumab extends survival in the NIAGARA trial.

Final OS analysis for cabozantinib plus atezolizumab

Negative final OS analysis for cabozantinib plus atezolizumab in mCRPC, but survival advantage seen in patients with liver or bone metastasis, and may be an option in select cases.

Ra-223 and 177Lu-PNT2002 – in metastatic castration-resistant prostate cancer

Late-breaking results provide evidence for efficacy benefits of radioisotopes – Ra-223 and 177Lu-PNT2002 – in metastatic castration-resistant prostate cancer mCRPC.

Targeted approaches for mCRC after progression

Data with novel combinations – cetuximab, amivantamab or ramucirumab plus chemotherapy – provide insights into the use of targeted approaches for mCRC after progression.

Air pollution impact on cancer is a recurrent theme at ESMO congresses

A study at ESMO24 explores an epidemiological view, adding to past findings on how PM2.5 triggers EGFR-mutant NSCLC and increases Breast Cancer risk linked to residential and workplace exposure.

For more updates on ESMO24, visit oncodaily.com